NETRIS Pharma is a biotechnology company developing pioneer targeted therapies for the treatment of cancer.

Its research is based on the innovative concept of Dependence Receptors.

NETRIS Pharma develops innovative anti-cancer drugs

NETRIS Pharma has a first candidate in the late stages of preclinical development, which targets the Netrin-1 ligand

Five other programs are in preclinical research stage

1
1

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group.

Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.

Our news
2014_logo_MENESR_horizontal_web

31st March, 2016: Agnes Bernet – Co-founder and CSO of NETRIS Pharma – is nominated as “Chevalier de la Légion d’Honneur”

| News | No Comments

NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – was nominated as “Chevalier de la Légion d’Honneur”, following the recommendation of Najat Vallaud-Belkacem, French Minister…

Prix IJC 2015

5th January, 2016: Agnes Bernet – Co-founder and CSO of NETRIS Pharma – received the 2015 Irène Joliot-Curie award

| News | No Comments

NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – received the 2015 Irène Joliot-Curie award from the French Minister of Education and Research and the…

beebanner_sm

19th-20th May, 2015: Stephane Depil – CEO of NETRIS Pharma – will attend the BioEquity Europe 2015 meeting in Vienna, Austria

| Event | No Comments

NETRIS Pharma will attend the BioEquity Europe 2015 meeting in Vienna, Austria (May 19th-20th). During the “Next Wave Companies” session, Stéphane Depil – CEO – will present NETRIS Pharma activities…

AM15_Logo

18th-22nd April, 2015: NETRIS Pharma will present recent data about NP137 preclinical development at the AACR Annual Meeting 2015 in Philadelphia, US

| Event | No Comments

NETRIS Pharma will attend the AACR Annual Meeting 2015 in Philadelphia, US (April 18th-22nd). For this occasion, NETRIS Pharma will present recent data regarding its first-in-class humanized anti-Netrin-1 antibody NP137,…

26th-EORTC-NCI-AACR

18th-21st November, 2014: NETRIS Pharma will attend the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain

| Event | No Comments
NETRIS Pharma will attend the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. For this occasion, NETRIS Pharma will present the preclinical characteristics of NP137, its...
logo_Site_retina-01

NETRIS Pharma presents its new website

| News | No Comments
NETRIS Pharma - a Lyon-based biotech firm aiming at translating the dependence receptor paradigm to the clinic - presents today its new website. This website introduces company missions, objectives, business...